1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bovilis BTV8 suspension for injection for cattle and sheep

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

One dose (1 ml) contains:

**Active substance:**

Bluetongue virus serotype 8 (prior to inactivation): 500 antigenic units*.

(* inducing a virus neutralising antibody response in chickens of ≥ 5.0 log₂)

**Adjuvants**

- Aluminium hydroxide (as 100%) 16.7 mg
- Saponin 0.31 mg.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Suspension for injection. Opalescent pink with resuspendable sediment.

4. **CLINICAL PARTICULARS**

4.1 **Target species**

Cattle and sheep.

4.2 **Indications for use, specifying the target species**

**Sheep**

To stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia*.

*(cycling value (Ct) > 30 by a validated rRT-PCR method, indicating absence of infectious virus)

**Cattle**

To stimulate active immunity in cattle from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia*.

*(for details see section 4.4)

Onset of immunity: 3 weeks after vaccination.
Duration of immunity: 6 months.

4.3 **Contraindications**

None.
4.4 Special warnings for each target species

This vaccine has been shown to reduce but not prevent viraemia in cattle. The extent of this reduction has been shown by epidemiological modelling studies to be likely to reduce virus transmission to an extent that can limit the spread of an outbreak in a vaccinated population. This vaccine has been tested for safety in sheep and cattle. If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.

No information is available on the use of the vaccine in seropositive animals, including those with maternally derived antibodies.

4.5 Special precautions for use

Special precautions for use in animals

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

In very rare cases vaccination may result in a slight rise in temperature (usually not more than 0.5 °C, in individual cases up to about 2 °C) for up to three days after vaccination, and temporary swellings at the injection site.

In sheep these swellings typically last for up to three weeks.

In cattle small palpable swellings may still be present up to six weeks after vaccination in approximately one third of the vaccinated animals.

In very rare cases hypersensitivity reactions may occur.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.

The safety and efficacy of the vaccine has not been established in breeding males. In these categories of animals the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or the national Competent Authorities, depending on the current vaccination policies against bluetongue virus.

4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Subcutaneous use.

Sheep
Primary vaccination:
Sheep from 1 month of age: injection of a single dose of 1 ml.

Revaccination:
As the duration of immunity is not yet fully established, any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.

Cattle
Primary vaccination:
Cattle from 6 weeks of age: injection of two doses of 1 ml, administered with an interval of approximately 3 weeks.

Revaccination:
As the duration of immunity is not yet fully established, any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.

Before using the vaccine allow it to reach ambient temperature (15–25 °C).
Shake the bottle before use and periodically during use.
Use clean and sterile vaccination equipment and avoid the introduction of contamination.
It is recommended to use a multijet vaccination system.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions other than those described in section 4.6 were observed following administration of a double dose in cattle and sheep. However, the temperature rise may be 0.5 °C higher and the swellings may be more pronounced and palpable for a longer period. In sheep, swellings may still be palpable after six weeks.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

ATCvet code: Sheep: QI04AA02
Cattle: QI02AA08
Inactivated viral vaccine, to stimulate active immunity against bluetongue virus serotype 8.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Trometamol
Sodium chloride
Maleic acid
Simeticone emulsion
Aluminium hydroxide
Saponin
Water for injection

6.2 Incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale for 10, 20, 50 ml vials: 2 years
Shelf life of the veterinary medicinal product as packaged for sale for 100, 200, 250, 500 ml vials: 1 year.
Shelf life after first opening the immediate packaging: 8 hours, provided the product is not subject to temperatures above 37 °C or contaminated.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

6.5 Nature and composition of immediate packaging

PET vials of 10, 20, 50, 100, 200, 250 or 500 ml, with a rubber stopper and aluminium cap.
Pack size: cardboard box with 1 or 10 vials.
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.

7. MARKETING AUTHORISATION HOLDER

Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The NETHERLANDS

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/106/001–014

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 06/09/2010.
Date of last renewal:
10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

The manufacture, import, possession, sale, supply and/or use of Bovilis BTV8 is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.

Any person intending to manufacture, import, possess, sell, supply and use Bovilis BTV8 must consult the relevant Member State’s competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.
ANNEX II

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The NETHERLANDS

Intervet International GmbH
Osterather Strasse 1a
50739 Köln
GERMANY

Name and address of the manufacturer responsible for batch release

Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The NETHERLANDS

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.

b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.

C. STATEMENT OF THE MRLs

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

A post inactivation antigen quantification test should be developed after the production of 10 commercial batches. The CVMP also agreed that the periodic safety update report (PSUR) cycle for would be re-started for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at three-yearly intervals.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING

Medicinal product no longer authorised
PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Cardboard box (10, 20, 50, 100, 200, 250 or 500 ml)

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
Vials (100, 200, 250 or 500 ml PET vials)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bovilis BTV8 suspension for injection for cattle and sheep

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Bluetongue virus serotype 8: 500 antigenic units/ml.

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

Vials:
100 ml
200 ml
250 ml
500 ml

Boxes:
10 ml 10 x 10 ml
20 ml 10 x 20 ml
50 ml 10 x 50 ml
100 ml 10 x 100 ml
200 ml 10 x 200 ml
250 ml 10 x 250 ml
500 ml 10 x 500 ml

5. TARGET SPECIES

Cattle and sheep

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.
8. **WITHDRAWAL PERIOD**

Withdrawal period: Zero days.

9. **SPECIAL WARNING(S), IF NECESSARY**

10. **EXPIRY DATE**

EXP {month/year}
Once broached, use within 8 hours.

11. **SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated.
Protect from light.
Do not freeze.

12. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

13. **THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

14. **THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

15. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Intervet International BV
Wim de Körverstraat 35,
5831 AN Boxmeer
The NETHERLANDS

16. **MARKETING AUTHORISATION NUMBER(S)**

EU/2/10/106/001
EU/2/10/106/002
17. MANUFACTURER'S BATCH NUMBER

Lot{number}
### MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

**Vials (10, 20 or 50 ml)**

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**
   
   Bovilis BTV8

2. **QUANTITY OF THE ACTIVE SUBSTANCE(S)**
   
   Bluetongue virus serotype 8: 500 antigenic units/ml.

3. **CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**
   
   10 ml  
   20 ml  
   50 ml

4. **ROUTE(S) OF ADMINISTRATION**
   
   S.C.

5. **WITHDRAWAL PERIOD**
   
   Withdrawal period: zero days

6. **BATCH NUMBER**
   
   Lot {number}

7. **EXPIRY DATE**
   
   EXP {month/year}  
   Once broached, use within 8 hours.

8. **THE WORDS “FOR ANIMAL TREATMENT ONLY”**
   
   For animal treatment only.
B. PACKAGE LEAFLET

Medicinal product no longer authorised
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The NETHERLANDS

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bovilis BTV8 suspension for injection for cattle and sheep

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

One dose (1 ml) contains:
Active ingredient: bluetongue virus serotype 8: 500 antigenic units*
(* inducing a virus neutralising antibody response in chickens of ≥ 5.0 log₂)
Adjuvants: aluminium hydroxide, saponin.
Opalescent pink with resuspendable sediment.

4. INDICATION(S)

Sheep
To stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia*.
*(cycling value (Ct) > 30 by a validated rRT-PCR method, indicating absence of infectious virus)

Cattle
To stimulate active immunity in cattle from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia*.
* (for details see section 12)

Onset of immunity: 3 weeks after vaccination.
Duration of immunity: 6 months.

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

In very rare cases vaccination may result in a slight rise in temperature (usually not more than 0.5 °C, in individual cases up to about 2 °C) for up to three days after vaccination, and temporary swellings at the injection site. In sheep, these swellings typically last for up to three weeks, while in cattle small palpable swellings may still be present up to six weeks after vaccination in approximately one third of
vaccinates. After administration of a double dose in cattle and sheep no other reactions were observed. However, the temperature rise may be 0.5 °C higher and the swellings may be more pronounced and palpable for a longer period. In sheep, swellings may still be palpable after six weeks. In very rare cases hypersensitivity reactions may occur.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Cattle and sheep.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Sheep
Primary vaccination:
Sheep from 1 month of age: subcutaneous injection of a single dose of 1 ml.

Revaccination:
As the duration of immunity is not yet fully established, any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation

Cattle
Primary vaccination:
Cattle from 6 weeks of age: subcutaneous injection of two doses of 1 ml, administered with an interval of approximately 3 weeks.

Revaccination:
As the duration of immunity is not yet fully established, any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.

9. ADVICE ON CORRECT ADMINISTRATION

Before using the vaccine allow it to reach ambient temperature (15–25 °C).
Shake the bottle before use and periodically during use.
Use clean and sterile vaccination equipment and avoid the introduction of contamination.
It is recommended to use a multiject vaccination system.

10. WITHDRAWAL PERIOD

Zero days.
11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C), protect from light, do not freeze.
Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after EXP. Once broached use within 8 hours, provided the product is not subject to temperatures above 37 °C or contaminated.

12. SPECIAL WARNING(S)

Special warnings for each target species:
This vaccine has been shown to reduce but not prevent viraemia in cattle. The extent of this reduction has been shown by epidemiological modelling studies to be likely to reduce virus transmission to an extent that can limit the spread of an outbreak in a vaccinated population.
This vaccine has been tested for safety in sheep and cattle.
If used in other domestic or wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.
No information is available on the use of the vaccine in seropositive animals, including those with maternally derived antibodies.

Special precautions for use in animals:
Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:
The vaccine can be used during pregnancy and lactation.

Fertility:
The safety and efficacy of the vaccine has not been established in breeding males. In these categories of animals the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or the national Competent Authorities, depending on the current vaccination policies against bluetongue virus.

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Incompatibilities:
Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help protect the environment.
14. **DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**


15. **OTHER INFORMATION**

Bovilis BTV8 is an inactivated viral vaccine, to stimulate active immunity against bluetongue virus serotype 8.
For animal treatment only.

The vaccine is presented in cardboard boxes with 1 or 10 PET vials containing 10, 20, 50, 100, 200, 250 or 500 ml, closed with a rubber stopper and aluminium cap.
Not all pack sizes may be marketed.

The manufacture, import, possession, sale, supply and/or use of Bovilis BTV8 is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.
Any person intending to manufacture, import, possess, sell, supply and use Bovilis BTV8 must consult the relevant Member State’s competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.